Paternal drug use: before and during pregnancy

Bibliography

• Trasler JM, Doerksen T. Teratogen update: paternal exposures-reproductive risks. Teratology 1999;60:161-72
   PubMedGoogle Scholar
• Nørgard B, Pedersen L, Jacobsen J, The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. Aliment Pharmacol Ther 2004;19:679-85
   PubMed Web of Science ®Google Scholar
• Stahl O, Boyd H, Giwercman A, Risk of birth abnormalities in the offspring of men with history of cancer: a cohort study using Danish and Swedish National Registries. J Natl Cancer Inst 2011;103:398-406
   PubMed Web of Science ®Google Scholar
• Amory JK, Wang C, Swerdloff RS, The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab 2007;92:1659-65
   PubMed Web of Science ®Google Scholar
• Tanrikut C, Feldman AS, Altemus M, Adverse effects of paroxetine on sperm. Fertil Steril 2010;94:1021-6
   PubMed Web of Science ®Google Scholar
• Lewis SEM, Aitken RJ. DNA damage to spermatozoa has impacts on fertilization and pregnancy. Cell Tissue Res 2005;322:33-41
   PubMed Web of Science ®Google Scholar
• Schirm E, Pedersen L, Tobi H, Drug use among fathers around time of conception: two register based surveys from Denmark and the Netherlands. Pharmacoepidemiol Drug Saf 2004;13:609-13
   PubMed Web of Science ®Google Scholar
• Engeland A, Bramness JG, Kjersti Daltveit A, Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106 000 pregnancies in Norway 2004-2006. Br J Clin Pharmacol 2008;65:653-60
   PubMed Web of Science ®Google Scholar
• De Santis M, Cesari E, Cavaliere A, Paternal exposure and counseling: experience of a teratology information service. Reprod Toxicol 2008;26:42-6
   PubMed Web of Science ®Google Scholar
• Hoeltzenbein M, Weber-Schoendorfer C, Paternal exposure to drugs – Is there an increased risk for congential abnormalities?: experience of the Berlin Institute for clinical teratology and drug risk assessment during pregnancy. Reprod Toxicol 2008;26:64
   Google Scholar
• Lee C, Jin C, Mata A, A pilot study of paternal drug exposure: the motherisk experience. Reprod Toxicol 2010;29:353-60
   PubMed Web of Science ®Google Scholar
• Cordier S. Evidence of a role of paternal exposures in developmental toxicity. Basic Clin Pharmacol Toxicol 2008;102:176-81
   PubMed Web of Science ®Google Scholar
• Available from: www.iadb.nl [Accessed 4 May 2011]
   Google Scholar
• Available from: www.whocc.no/atc [Accessed 2 August 2011]
   Google Scholar
• Vegter S, Kolling P, Toben M, Replacing hormone therapy-is the decline in prescribing sustained, and are nonhormonal drugs substituted? Menopause 2009;16:329-35
   PubMed Web of Science ®Google Scholar
• Tobi H, van den Berg PB, de Jong-van den Berg LTW. The interaction database: synergy of science and practice in pharmacy. In: Brause RW, Hanisch E, editors. Medical Data Analysis. Springer, Berlin Heidelberg; New York: 2000. p. 206-11
   Google Scholar
• Nationaal Kompas Volksgezondheid. Available from: www.nationaalkompas.nl [Accessed 22 September 2011]
   Google Scholar
• Viktil K, Engeland A, Furu K. Use of antirheumatic drugs in mothers and fathers before and during pregnancy – a population-based cohort study. Pharmacoepidemiol Drug Saf 2009;18:737-42
   PubMed Web of Science ®Google Scholar
• Boyce P, Condon J, Barton J, Corkindale C. First-time fathers' study: psychological distress in expectant fathers during pregnancy. Aust N Z J Psychiatry 2007;41:718-25
   PubMed Web of Science ®Google Scholar
• Paulson JF, Bazemore SD. Prenatal and postpartum depression in fathers and its association with maternal depression. JAMA 2010;303:1961-9
   PubMed Web of Science ®Google Scholar
• Green DM, Whitton JA, Stovall M, Pregnancy outcome of partners of male survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 2003;21:716-21
   PubMed Web of Science ®Google Scholar
• Beghin D, Cournot M-P, Vauzelle C, Elefant E. Paternal exposure to methotrexate and pregnancy outcomes. J Rheumatol 2011;35:628-32
   Google Scholar
• Trojan J, Kronenberger B, von Wagner M, Zeuzem S. Lack of birth defects after paternal exposure to lamivudine. J Hepatol 2002;36:571
   PubMed Web of Science ®Google Scholar
• Teruel C, Lopez-San Roman A, Bermejo F, Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines. Am J Gastroenterol 2010;105:2003-8
   PubMed Web of Science ®Google Scholar
• Rajapakse R, Korelitz B, Zlatanic J, Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 2000;95:684-8
   PubMed Web of Science ®Google Scholar
• De Santis M, Carducci B, Cavaliere A, Case Report – Paternal exposure to ribavirin: pregnancy and neonatal outcome. Antivir Ther 2003;8:73-5
   PubMed Web of Science ®Google Scholar
• Taguchi N, Shinya I. Paternal use of ribavirin-interferon alpha B2 combination therapy before conception. Can Fam Physician 2005;26:42-6
   Google Scholar
• Liu K, Binsaleh S, Lo K, Jarvi K. Propecia-induced spermatogenic failure: a report of two cases. Fertil Steril 2008;90:849.e17-19
   Web of Science ®Google Scholar
• Patel A, Rivkees S. Case Report – Prenatal virilization associated with paternal testosterone gel therapy. Int J Pediatr Endocrinol 2010;2010:867471
   PubMedGoogle Scholar
• Davis DL, Friedler G, Mattison D, Morris R. Male-mediated tertogenesis and other reproductive effect: biologic and epidemiologic findings and a plea for clinical research. Reprod Toxicol 1992;6:289-92
   PubMed Web of Science ®Google Scholar